Clofarabine: A new treatment option for patients with acute myeloid leukemia

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1353-1357

  Larson, Melissa L ^a   Venugopal, Parameswaran ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapy; Clofarabine; Elderly

Indexed keywords

CLADRIBINE; CLOFARABINE; CYTARABINE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CYTOGENETICS; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; RASH; REVIEW;

ADENINE NUCLEOTIDES; ADULT; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 67649716634     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902997990     Document Type: Review

References (18)

1. Surveillance epidemiology and end results: National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/amyl.html [Last accessed 10 March 2009]
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485 • A retrospective analysis demonstrating the difference age makes in acute myeloid leukemia.
3. Leith CP, Chir B, Kopecky KJ, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-3329 (Pubitemid 27229818)
4. Leith CP, Kopecky KJ, Chen I-M, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/p-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999;94:1086-1099
5. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-1603 (Pubitemid 34773427)
6. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-1915 (Pubitemid 46854425)
7. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462
8. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903 (Pubitemid 24299870)
9. Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leuk Lymph 2007;48:1922-1930 • This review provides a comprehensive overview of the mechanism of action of clofarabine. (Pubitemid 47542978)
10. Faderl S, Gandhi S, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947 (Pubitemid 40170859)
11. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173 (Pubitemid 46594149)
12. Kantarjian HM, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386 (Pubitemid 37193573)
13. Burnett AK, Russell N, Kell JW, et al. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004;104:248a
14. Burnett AK, Baccarani M, Johnson P, et al. A phase II study (BIOV-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood 2006;108:130a (Pubitemid 44776862)
15. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-1124 (Pubitemid 46435390)
16. Erba HP, Kantarjian H, Claxton DF, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 2008;112:209
17. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51 (Pubitemid 43990611)
18. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-1645